Reports
Sale
Dyspnea Market Size, Share, Growth, Analysis, Forecast: By Treatment Type: Supplemental Oxygen Therapy, Relaxation Therapy; By Drug Class: Antianxiety, Antibiotics, Anticholinergic Agents, Corticosteroids, Others; By Route of Administration: Oral, Inhalation, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Dyspnea Market Outlook
The global dyspnea market size was valued at USD 6.5 billion in 2023, driven by increasing prevalence of respiratory disorders across the 8 major markets. The market is expected to grow at a CAGR of 6.9% during the forecast period of 2024-2032, with the values likely to rise from USD 6.9 billion in 2024 to USD 11.8 billion by 2032.
Dyspnea Market Overview
Dyspnea involves breathlessness or breathing discomfort characterized by distinct sensations that vary in intensity. It may occur due to heavy physical exertion, or as a side effect of asthma, cardiac ischemia, pneumonia, and congestive heart failure, among others. Dyspnea has become more common after COVID-19, as the virus primarily attacked the lungs of patients. As per a study conducted in 76 patients, clinical meaningful dyspnea affected 49% of the patients at 3 months, while 24% of the patients experienced the symptoms getting worse between 3-12 after COVID-19 exposure.
The dyspnea market growth is driven by the advent of targeted therapies modes, aimed to offer effective treatment. The market is experiencing a surge in research and development activities for the development of new drugs and therapies. The increasing prevalence of respiratory disorders such as asthma, pneumonia, myocardial ischemia, and other respiratory disorders globally is a major factor contributing to the market share. The market is further expected to be driven by the rising prevalence of indoor as well as outdoor pollution. The rising expenditure on the development of healthcare infrastructure is another major factor bolstering the market value.
FDA Approvals to Develop Effective Treatment Alternative to Patients
The market is expected to experience significant growth driven by the increased prevalence of respiratory disorders such as asthma. To meet the dyspnea market demand, there has been a surge in new drug developments and their FDA approvals. For instance, in January 2023, the U.S. FDA approved Airsupra, an inhalational aerosol to treat asthma in adults (18 or older). Administered as a combination of albuterol and budesonide, it is the foremost combination of an inhaled corticosteroid and short-acting beta-agonist. The increasing incidence of FDA approvals is expected to fill a crucial gap of unmet needs in asthma treatment. In addition, increasing drug approvals are also expected to spark competition among key players, bolstering the market growth in the forecast period.
Surge in Investments to Drive Market Growth
The increased initiatives from the government to spread awareness about respiratory disorders and to get diagnosed in time for appropriate treatment are some of the significant dyspnea market trends. Moreover, an increasing number of funding activities to fetch treatments for asthma and other respiratory are collectively influencing market growth. For instance, in October 2023, San Francisco and London-based Aiolos Bio (a new startup with an asthma drug in clinical trials) declared that it raised USD 245 million in Series A funding. Such fundings support the development of drugs for clinical treatment, leading to expansion of the market.
Dyspnea Market Segmentations
Market Breakup by Treatment Type
- Supplemental Oxygen Therapy
- Relaxation Therapy
Market Breakup by Drug Class
- Antianxiety
- Antibiotics
- Anticholinergic Agents
- Corticosteroids
- Others
Market Breakup by Route of Administration
- Oral
- Inhalation
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Ambulatory Services
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Dyspnea Market Regional Analysis
North America is leading the regional market, driven by the presence of advanced treatments and the availability of distribution channels to access appropriate drugs for treatment. The presence of a robust healthcare system is a major factor attributing to the growth of the region. In November 2023, Dupixent® (dupilumab ), Sanofi’s investigational drug for treating COPD showed positive results in the Phase 3 BOREAS trial. The drug reduced COPD exacerbations by 34%. As a part of the results, it was also revealed that the drug offered improvement in lung function by 12 weeks, and it was sustained at 52 weeks. The existence of prominent healthcare companies attribute to the dyspnea market share in the region.
Europe, having several research and academic institutions holds a significant market share. In addition, a huge geriatric population base is expected to increase the demand for dyspnea treatment in the forecast period.
Asia Pacific is poised to witness significant growth, owing to rising investments in improving the medical infrastructure. There has been substantial development and prevalence for alternative therapies to treat the condition in patients. The amalgamation of traditional medicine with novel techniques is anticipated to drive the dyspnea market size in the region.
Dyspnea Market: Competitor Landscape
In July 2023, Lupin Limited , revealed that its Australian subsidiary, Generic Health Pty Ltd, received approval for Tiotropium 18 micrograms powder for inhalation from Therapeutic Goods Administration (TGA). The approved drug can be used in combination with Lupin Haler and is indicated treating long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD). It has also been found effective in preventing COPD exacerbations. The surge in drug approvals from key regulatory authorities has been a major market trend, expected to boost the market size in the forecast period.
The key features of the dyspnea market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bausch Health
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
- Ligand Pharmaceuticals Incorporated
- Amneal Pharmaceuticals LLC
- Jazz Pharmaceuticals, Inc.
- Mylan N.V.
- Lupin
- Pfizer Inc.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma
- Nephron Pharmaceuticals Corporation
- Zydus Cadila
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dyspnea Market Overview – 8 Major Markets
3.1 Dyspnea Market Historical Value (2017-2023)
3.2 Dyspnea Market Forecast Value (2024-2032)
4 Dyspnea Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Dyspnea Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Dyspnea Epidemiology Scenario and Forecast (2017-2032)
6.5 China Dyspnea Epidemiology Scenario and Forecast (2017-2032)
7 Dyspnea Market Landscape – 8 Major Markets
7.1 Dyspnea: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dyspnea: Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Drug Class
8 Dyspnea Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dyspnea Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dyspnea Market Segmentation (2017-2032) - 8 Major Markets
11.1 Dyspnea Market (2017-2032) by Treatment Type
11.1.1 Market Overview
11.1.2 Supplemental Oxygen Therapy
11.1.3 Relaxation Therapy
11.2 Dyspnea Market (2017-2032) by Drug Class
11.2.1 Market Overview
11.2.2 Antianxiety
11.2.3 Antibiotics
11.2.4 Anticholinergic Agents
11.2.5 Corticosteroids
11.2.6 Others
11.3 Dyspnea Market (2017-2032) by Route of Administration
11.3.1 Oral
11.3.2 Inhalation
11.3.3 Others
11.4 Dyspnea Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Ambulatory Services
11.4.6 Others
11.5 Dyspnea Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 China
12 United States Dyspnea Market (2017-2032)
12.1 United States Dyspnea Market Historical Value (2017-2023)
12.2 United States Dyspnea Market Forecast Value (2024-2032)
12.3 United States Dyspnea Market (2017-2032) by Treatment Type
12.3.1 Market Overview
12.3.2 Supplemental Oxygen Therapy
12.3.3 Relaxation Therapy
12.4 United States Dyspnea Market (2017-2032) by Drug Class
12.4.1 Market Overview
12.4.2 Antianxiety
12.4.3 Antibiotics
12.4.4 Anticholinergic Agents
12.4.5 Corticosteroids
12.4.6 Others
13 EU-4 and United Kingdom Dyspnea Market (2017-2032)
13.1 EU-4 and United Kingdom Dyspnea Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Dyspnea Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Dyspnea Market (2017-2032) by Treatment Type
13.3.1 Market Overview
13.3.2 Supplemental Oxygen Therapy
13.3.3 Relaxation Therapy
13.4 EU-4 and United Kingdom Dyspnea Market (2017-2032) by Drug Class
13.4.1 Market Overview
13.4.2 Antianxiety
13.4.3 Antibiotics
13.4.4 Anticholinergic Agents
13.4.5 Corticosteroids
13.4.6 Others
14 Japan Dyspnea Market
14.1 Japan Dyspnea Market Historical Value (2017-2023)
14.2 Japan Dyspnea Market Forecast Value (2024-2032)
14.3 Japan Dyspnea Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Supplemental Oxygen Therapy
14.3.3 Relaxation Therapy
14.4 Japan Dyspnea Market (2017-2032) by Drug Class
14.4.1 Market Overview
14.4.2 Antianxiety
14.4.3 Antibiotics
14.4.4 Anticholinergic Agents
14.4.5 Corticosteroids
14.4.6 Others
15 China Dyspnea Market
15.1 China Dyspnea Market (2017-2032) Historical Value (2017-2023)
15.2 China Dyspnea Market (2017-2032) Forecast Value (2024-2032)
15.3 China Dyspnea Market (2017-2032) by Treatment Type
15.3.1 Market Overview
15.3.2 Supplemental Oxygen Therapy
15.3.3 Relaxation Therapy
15.4 China Dyspnea Market (2017-2032) by Drug Class
15.4.1 Market Overview
15.4.2 Antianxiety
15.4.3 Antibiotics
15.4.4 Anticholinergic Agents
15.4.5 Corticosteroids
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Bausch Health
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 GlaxoSmithKline plc
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Teva Pharmaceutical Industries Ltd
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Ligand Pharmaceuticals Incorporated
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Amneal Pharmaceuticals LLC
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Jazz Pharmaceuticals, Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Mylan N.V.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Lupin
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Pfizer Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Novartis AG
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Boehringer Ingelheim International GmbH
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Sun Pharmaceutical Industries Ltd
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Aurobindo Pharma
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Nephron Pharmaceuticals Corporation
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Zydus Cadila
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
List not exhaustive
23 Dyspnea Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 6.5 billion in 2023 driven by the rising prevalence of respiratory diseases across the 8 major markets.
The market is anticipated to grow at a CAGR of 6.9% during the forecast period, likely to reach a market value of USD 11.8 billion by 2032.
The increasing prevalence of indoor and outdoor pollutants, increased initiatives by the government to spread awareness among people regarding dyspnea and its treatments, increased prevalence of COPD, and increased FDA approvals are major factors contributing to the market demand.
The increasing number of clinical trials examining the efficacy of drugs, leading to growth in drug approvals from essential regulatory bodies is a major market trend. In July 2023, Lupin's Tiotropium 18 micrograms powder received approval from Therapeutic Goods Administration (TGA) to treat long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD).
The major regions of the market include United States, EU-4, the United Kingdom, Japan, and China. EU-4 is further divided into Germany, France, Italy, and Spain.
Types of treatments in the market include supplemental oxygen therapy and relaxation therapy.
Types of drug classes used for dyspnea treatment are antianxiety, antibiotics, anticholinergic agents, corticosteroids, and others.
The routes of administration include oral and inhalation, among others.
End users in the market include hospitals, specialty clinics, homecare, ambulatory services, and others.
Key players involved in the market are Bausch Health, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Amneal Pharmaceuticals LLC, Jazz Pharmaceuticals, Inc., Mylan N.V., Lupin, Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Nephron Pharmaceuticals Corporation, and Zydus Cadila.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER